Table 4 DAS28 remission rates at week 16 for DMARD IR (LOT) patients stratified by SNPs achieving confirmation in LM

From: Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis

Marker

LOT freq

DAS28 remission rate (%)

  

BM+

BM−

Δ

rs7055107

0.30

28.4

18.9

9.4

rs7055107 or rs9594987

0.45

28.4

16.2

12.2

rs7055107 and rs4910008

0.21

33.3

18.8

14.5

rs7055107 or rs9594987 or rs11052877

0.78

24.4

12.5

11.9

rs7055107 and rs703505 and rs10108210

0.20

31.8

19.2

12.6

  1. Abbreviations: BM+, biomarker positive; BM−, biomarker negative; DAS28, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; IR, inadequate responder; LM, LITHE and MEASURE; LOT, LITHE, OPTION, and TOWARD; SNP, single-nucleotide polymorphism.
  2. Placebo-corrected remission rates and frequency are shown from patients carrying polymorphisms (biomarker positive) and those not carrying the polymorphisms (biomarker negative). Delta (Δ) represents the difference in remission rate between BM+ and BM−. Only combinations yielding the best Δ for each model are shown. Only 8 mg kg−1 tocilizumab-treated patients were considered in this analysis owing to the far higher remission rates observed with this dose.28
Back to article page